<DOC>
	<DOCNO>NCT02184988</DOCNO>
	<brief_summary>The purpose study demonstrate safety multiple dose DWP-450 ( Botulinum purify neurotoxin , Type A ) Injection treatment moderate severe glabellar line adult subject .</brief_summary>
	<brief_title>Safety Study DWP-450 ( Botulinum Purified Neurotoxin , Type A ) Injection Treat Glabellar Lines</brief_title>
	<detailed_description>Three hundred fifty subject enrol injected study drug DWP-450 course 365 day study . Subjects moderate severe glabellar line maximum frown 4 point Glabellar Line Scale ( GLS , 0=none , 1= mild , 2=moderate , 3=severe ) , judge investigator , eligible injection DWP-450 . After injection , subject follow eligible repeat injection GLS ≥2 maximum frown , judge Investigator . If subject GLS≥2 follow monthly eligible repeat treatment . Subjects may receive maximum 4 treatment follow 365 day initial treatment .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<criteria>Inclusion Criteria ( A subject must meet follow inclusion criterion order eligible enrollment study ) : Subjects must adult 18 year age Subject able provide inform consent comply study instruction Subject moderate severe glabellar line maximum frown assess investigator use GLS Subject willing able complete entire course study Exclusion Criteria ( A subject must meet follow exclusion criterion order eligible enrollment stud ) : Previous treatment botulinum toxin serotype forehead area within last 8 month Previous treatment facial aesthetic procedure ( e.g . injection filler , chemical peeling , photo rejuvenation ) glabellar area within last 12 month Previous insertion permanent material glabellar area Planned treatment botulinum toxin serotype body region study period Any surgery glabellar area include surgical removal corrugator , procerus , depressor supercilii muscle combination , scar glabellar area surround area ( include eye brow ) Energy base cryotherapy base treatment facial muscle superior lateral canthus Any plan facial aesthetic procedure trial period , superior level lateral canthus ( subject continue usual skin care routine ) Inability substantially lessen glabellar frown line even physically spread apart Marked facial asymmetry Ptosis eyelid and/or eyebrow , history eyelid and/or eyebrow ptosis History facial nerve palsy Excessive dermatochalasis , deep dermal scarring , thick sebaceous skin Any active infection area injection sit Medical condition may affect neuromuscular function ( e.g. , myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis ) Evidence recent alcohol drug abuse Medical psychiatric condition may increase risk associate study participation may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study Pregnant sexually active female subject childbearing potential willing use acceptable form contraception Known allergy hypersensitivity botulinum toxin preparation Participation another interventional clinical study within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Glabellar Lines</keyword>
	<keyword>Botulinum purifies neurotoxin , Type A ( DWP-450 )</keyword>
</DOC>